NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeoGenomics Inc (NEO) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock's technical indicators show bearish trends, and recent financial performance reflects declining profitability. While analysts maintain positive ratings with increased price targets, the lack of strong trading signals, neutral sentiment from hedge funds and insiders, and no significant positive catalysts suggest that waiting for a better entry point may be prudent.
The MACD is positive and expanding, indicating a slight bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 7.701), with resistance levels at R1: 8.388 and R2: 8.601. Overall, the technical indicators suggest a bearish trend.
Analysts have raised price targets recently, with Piper Sandler increasing the target to $13 and TD Cowen raising it to $16, reflecting confidence in the company's potential. Additionally, the company's revenue grew by 10.56% YoY in Q4 2025.
Gross margin also declined slightly. There are no significant insider or hedge fund trading trends, and the stock has a 60% chance of declining further in the short term based on historical patterns.
In Q4 2025, NeoGenomics reported a revenue increase of 10.56% YoY to $190.17 million. However, net income dropped to -$9.88 million (-35.52% YoY), and EPS fell to -$0.08 (-33.33% YoY). Gross margin decreased to 43.83%, down 2.43% YoY, indicating declining profitability.
Analysts are optimistic, with Piper Sandler and TD Cowen raising price targets to $13 and $16, respectively, and maintaining Overweight/Buy ratings. This reflects confidence in the company's long-term potential despite current challenges.
